Gilead Sciences (GILD) 117.86 $GILD
Ischemia Reperfusion Injury Pipeline Review, H1 2015 - 24 Companies & 63 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mw2sb6/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adienne Pharma & Biotech - Alligator Bioscience AB - Antipodean Pharmaceuticals, Inc. - BioLineRx, Ltd. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Catalyst Biosciences, Inc. - Curatis Pharma GmbH - Gilead Sciences, Inc. - Ischemix - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Mercury Pharmaceuticals, Inc. - Omeros Corporation - Opsona Therapeutics Ltd. - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. - Prothix BV - Trophos SA - Zealand Pharma A/S - Zyrnat Biotherapeutics SL Drug Profiles - ADC-1004 - AM/AMBP-1 - ANV-6L15 - APP-103 - BBT-030 - BBT-045 - BL-7060 - C1 esterase inhibitor (recombinant) - CB-2782 - CMX-2043 - CRX-526 - Curaglutide - danegaptide - Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Elafin - EP-80317 - Ergidina - GS-459679 - KN-93 - KR-62980 - LSNTU-106 - mangafodipir - MFH-244 - MG-53 - mirococept - MitoQ - Monoclonal Antibody for Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury - MTP-131 - NBD Peptide - NecX - Neutrolide - NOXD-21 For more information visit http://www.researchandmarkets.com/research/mw2sb6/ischemia
GILD: 117.86 (-0.04), OMER: 16.10 (-0.06)
Atherosclerosis Pipeline Review, H1 2015 - 42 Companies & 105 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfrcbq/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - advanceCor GmbH - AFFiRiS AG - Arisaph Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca Plc - Athera Biotechnologies AB - AtheroNova Inc. - AuraSense Therapeutics, LLC - Bayer AG - Bridge Bioresearch Plc - Campus Technologies Freiburg GmbH - Cardax Pharmaceuticals, Inc. - ChemoCentryx, Inc. - CohBar Inc. - DoNatur GmbH - Dr. Reddy's Laboratories Limited - Dybly AG - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GenKyoTex S.A. - Gilead Sciences, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - KineMed, Inc. - Kowa Company, Ltd. - Lead Discovery Center GmbH - MedImmune, LLC - Merck & Co., Inc. - MI.TO. Technology S.r.L. - Novartis AG - Omeros Corporation - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. For more information visit http://www.researchandmarkets.com/research/pf...osclerosis
KNMD: (), LLY: 84.51 (-0.03), OMER: 16.10 (-0.06), JNJ: 100.21 (+0.37), ISIS: 54.93 (+1.76), OPK: 16.37 (-0.01), GILD: 117.86 (-0.04), AZN: 33.79 (+0.05), MRK: 58.96 (+0.44), CCXI: 8.24 (-0.30), NVS: 103.75 (+0.57)
Critical Alerts For Fitbit, Gilead Sciences, American Airlines, Skechers and JetBlue Released By InvestorsObserver
PR Newswire - Fri Jul 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FIT, GILD, AAL, SKX and JBLU.
FIT: 47.60 (+2.41), GILD: 117.86 (-0.04), SKX: 150.45 (+1.46), AAL: 40.10 (-0.17), JBLU: 22.98 (+0.12)
Global Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Pipeline Report 2015 - Analysis of 31 Companies & 44 Drug Profiles
M2 - Fri Jul 31, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5m2c5s/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - ImmunoGen, Inc. - Immunomedics, Inc. - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Neopharm Ltd. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - SpectraMab GmbH - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. Drug Profiles - 4SC-202 - ACP-196 - afuresertib hydrochloride - AGS-67E - AT-7519 - AZD-6738 - BI-836826 - BMS-986016 - buparlisib hydrochloride - CBM-C19.1 - CBM-C20.1 - CC-122 - Cell Therapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - cerdulatinib - duvelisib - evofosfamide - FBTA-05 - GS-9901 - IMGN-529 - IMMU-114 - IPH-2201 - JCAR-014 - JCAR-015 - MEDI-551 - MOR-208 - moxetumomab pasudotox - nivolumab - obinutuzumab - pilaralisib - S-055746 - selinexor - spebrutinib besylate - TAK-659 - TGR-1202 - tisagenlecleucel-T For more information visit http://www.researchandmarkets.com/research/5m2c5s/refractory
IMMU: 2.05 (-0.06), PTLA: 49.44 (+0.53), IMGN: 18.02 (+0.12), TGTX: 17.45 (+0.39), BMY: 65.64 (+1.18), GSK: 43.44 (-0.15), GILD: 117.86 (-0.04), AZN: 33.79 (+0.05), JUNO: 48.92 (+1.15), INFI: 8.74 (+0.01), ABBV: 70.01 (-0.15), CBMG: 27.95 (+0.87), NVS: 103.75 (+0.57), KPTI: 20.52 (+0.44), CELGZ: 2.04 (+0.01)
1% Q2 Profit Growth Is S&P 500's Weakest Since '12
at Investor's Business Daily - Fri Jul 31, 7:02AM CDT
Six companies now are keeping the second-quarter earnings growth rate in positive territory for S&P 500 businesses, and that may suggest more softness to come. With 64% of S&P 500 companies having reported their performance in the last calendar...
DHI: 29.69 (+0.22), CCI: 81.91 (+0.44), F: 14.83 (-0.27), EMN: 78.40 (-0.19), FB: 94.01 (-1.20), UTX: 100.31 (-0.42), C: 58.46 (-0.42), WMT: 71.98 (-0.18), COP: 50.34 (-1.73), BAC: 17.88 (-0.25), AA: 9.87 (-0.11), LEN: 53.04 (+0.86), GILD: 117.86 (-0.04), CHK: 8.66 (-0.31), PHM: 20.72 (+0.32), GM: 31.51 (-0.40), GOOGL: 657.50 (-7.06), CAT: 78.63 (+0.28), CVX: 88.48 (-4.55), DOW: 47.06 (-0.36), AAPL: 121.30 (-1.07), VZ: 46.79 (+0.12)
Nokia and Whole Foods are big market movers
AP - Thu Jul 30, 3:24PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
WFM: 36.40 (+0.32), NHTC: 30.30 (-2.07), CNHI: 8.97 (unch), WYNN: 103.23 (-0.89), GSK: 43.44 (-0.15), CYT: 74.23 (-0.01), WDC: 86.06 (-0.38), NOK: 7.05 (+0.02), ATML: 8.28 (-0.14), GILD: 117.86 (-0.04), TMUS: 40.66 (+1.80), PG: 76.70 (-0.69), TWTR: 31.01 (-0.46), HOLX: 41.66 (+0.91)
Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)
Stock Market News for July 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 9:10AM CDT
Benchmarks ended higher on Wednesday after Fed’s policymakers kept key interest rates unchanged and acknowledged that the economy and job market are strengthening
RIG: 13.26 (-0.69), GILD: 117.86 (-0.04), NOC: 173.01 (-2.40), IP: 47.87 (+0.40), COP: 50.34 (-1.73), XOM: 79.21 (-3.80), CVX: 88.48 (-4.55), SLB: 82.82 (-0.70), MA: 97.40 (-1.01)
Gilead's Hepatitis C Dominance Unchecked By AbbVie
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 30, 7:04AM CDT
Source: Gilead Sciences via Google Maps. Worries that Gilead Sciences market dominance in treating hepatitis C would falter following the launch of AbbVie 's Viekira Pak this year have been mostly curbed after Gilead Sciences' stellar second...
GILD: 117.86 (-0.04), ABBV: 70.01 (-0.15)
Gilead Sciences Rises 2.33% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 29, 3:43PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $115.11 to a high of $119.46. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $117.15 on volume of 23.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 117.86 (-0.04)
Watch for Gilead Sciences to Potentially Pullback After Gaining 2.33% Yesterday
Comtex SmarTrend(R) - Wed Jul 29, 3:42PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $115.11 to a high of $119.46. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $117.15 on volume of 23.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 117.86 (-0.04)
Stocks Rally in Relief as Fed Stays Mum on September Hike
at The Street - Wed Jul 29, 3:11PM CDT
Stocks rally into the close after the Federal Reserve keeps rates unchanged.
TOT: 49.29 (+0.09), GILD: 117.86 (-0.04), COP: 50.34 (-1.73), YELP: 26.40 (+0.37), TWTR: 31.01 (-0.46), PTR: 98.39 (-1.72), SLB: 82.82 (-0.70), MA: 97.40 (-1.01), XLE: 69.38 (-1.55), HUM: 182.09 (-1.61)
Two Little Headlines and the End of Health Care
Dave Gonigam - Daily Reckoning - Wed Jul 29, 2:27PM CDT
This post Two Little Headlines and the End of Health Care appeared first on Daily Reckoning . Dave Gonigam explores the end of health care as we know it. Plus: What if we paid for groceries the way we pay for health care? And: Can you keep your...
GILD: 117.86 (-0.04)
Stocks Are Higher After Fed Leaves Rates Unchanged
at The Street - Wed Jul 29, 1:54PM CDT
Stocks extend session highs after the Federal Reserve leaves interest rates unchanged.
GILD: 117.86 (-0.04), COP: 50.34 (-1.73), YELP: 26.40 (+0.37), TWTR: 31.01 (-0.46), MA: 97.40 (-1.01), HUM: 182.09 (-1.61)
Q2 Earnings Season Halftime Report
ESTMZ - Wed Jul 29, 1:47PM CDT
And just like that, we’re already at the midpoint of the second quarter earnings season. Technically, we’re past that, with 264 S&P 500 companies reporting. As usual, we are in much better standing in regards to growth than we were at the...
VLO: 65.60 (+1.37), SPY: 210.50 (-0.32), GILD: 117.86 (-0.04), FB: 94.01 (-1.20), XOM: 79.21 (-3.80), CVX: 88.48 (-4.55), TWTR: 31.01 (-0.46), AAPL: 121.30 (-1.07), GOOG: 625.61 (-6.98), CELG: 131.25 (-0.63)
5 Big Stocks on Traders' Radars -- and What You Should Do With Them Now
at The Street - Wed Jul 29, 1:37PM CDT
Here's a technical look at how to trade some of the most active stocks on the market right now.
MU: 18.51 (-1.39), GILD: 117.86 (-0.04), CFG: 26.07 (-0.42), X: 19.47 (-0.62), BLDR: 15.04 (+0.29)
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Wed Jul 29, 11:30AM CDT
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 3.39 (+0.03), KNMD: (), VTAE: 10.11 (+0.08), LLY: 84.51 (-0.03), OMER: 16.10 (-0.06), JNJ: 100.21 (+0.37), ISIS: 54.93 (+1.76), OPK: 16.37 (-0.01), GILD: 117.86 (-0.04), AZN: 33.79 (+0.05), MRK: 58.96 (+0.44), CCXI: 8.24 (-0.30), VBLT: 6.00 (+0.02), NVS: 103.75 (+0.57)
Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - Wed Jul 29, 11:29AM CDT
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 117.86 (-0.04), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)
Stocks Turn Positive as Crude Inventories Drop
at The Street - Wed Jul 29, 9:50AM CDT
Stocks turn positive on Wednesday after a steeper-than-expected drop in crude supplies.
ANTM: 154.27 (-0.62), GILD: 117.86 (-0.04), YELP: 26.40 (+0.37), TWTR: 31.01 (-0.46), MA: 97.40 (-1.01), HUM: 182.09 (-1.61)
Cramer -- Gilead Has a ‘Fabulous’ Quarter, Tons of Merger Opportunities
at The Street - Wed Jul 29, 9:35AM CDT
Gilead Sciences not only beat earnings estimates but it can make a massive acquisition should it want to do so, Cramer says.
GILD: 117.86 (-0.04), XBI: 255.44 (+2.98), IBB: 382.53 (+3.73)
Ischemia Reperfusion Injury Pipeline Review, H1 2015 - 24 Companies & 63 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mw2sb6/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adienne Pharma & Biotech - Alligator Bioscience AB - Antipodean Pharmaceuticals, Inc. - BioLineRx, Ltd. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Catalyst Biosciences, Inc. - Curatis Pharma GmbH - Gilead Sciences, Inc. - Ischemix - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Mercury Pharmaceuticals, Inc. - Omeros Corporation - Opsona Therapeutics Ltd. - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. - Prothix BV - Trophos SA - Zealand Pharma A/S - Zyrnat Biotherapeutics SL Drug Profiles - ADC-1004 - AM/AMBP-1 - ANV-6L15 - APP-103 - BBT-030 - BBT-045 - BL-7060 - C1 esterase inhibitor (recombinant) - CB-2782 - CMX-2043 - CRX-526 - Curaglutide - danegaptide - Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Elafin - EP-80317 - Ergidina - GS-459679 - KN-93 - KR-62980 - LSNTU-106 - mangafodipir - MFH-244 - MG-53 - mirococept - MitoQ - Monoclonal Antibody for Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury - MTP-131 - NBD Peptide - NecX - Neutrolide - NOXD-21 For more information visit http://www.researchandmarkets.com/research/mw2sb6/ischemia
GILD: 117.86 (-0.04), OMER: 16.10 (-0.06)
Atherosclerosis Pipeline Review, H1 2015 - 42 Companies & 105 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfrcbq/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - advanceCor GmbH - AFFiRiS AG - Arisaph Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca Plc - Athera Biotechnologies AB - AtheroNova Inc. - AuraSense Therapeutics, LLC - Bayer AG - Bridge Bioresearch Plc - Campus Technologies Freiburg GmbH - Cardax Pharmaceuticals, Inc. - ChemoCentryx, Inc. - CohBar Inc. - DoNatur GmbH - Dr. Reddy's Laboratories Limited - Dybly AG - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GenKyoTex S.A. - Gilead Sciences, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - KineMed, Inc. - Kowa Company, Ltd. - Lead Discovery Center GmbH - MedImmune, LLC - Merck & Co., Inc. - MI.TO. Technology S.r.L. - Novartis AG - Omeros Corporation - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. For more information visit http://www.researchandmarkets.com/research/pf...osclerosis
KNMD: (), LLY: 84.51 (-0.03), OMER: 16.10 (-0.06), JNJ: 100.21 (+0.37), ISIS: 54.93 (+1.76), OPK: 16.37 (-0.01), GILD: 117.86 (-0.04), AZN: 33.79 (+0.05), MRK: 58.96 (+0.44), CCXI: 8.24 (-0.30), NVS: 103.75 (+0.57)
Critical Alerts For Fitbit, Gilead Sciences, American Airlines, Skechers and JetBlue Released By InvestorsObserver
PR Newswire - Fri Jul 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FIT, GILD, AAL, SKX and JBLU.
FIT: 47.60 (+2.41), GILD: 117.86 (-0.04), SKX: 150.45 (+1.46), AAL: 40.10 (-0.17), JBLU: 22.98 (+0.12)
Global Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Pipeline Report 2015 - Analysis of 31 Companies & 44 Drug Profiles
M2 - Fri Jul 31, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5m2c5s/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - ImmunoGen, Inc. - Immunomedics, Inc. - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Neopharm Ltd. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - SpectraMab GmbH - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. Drug Profiles - 4SC-202 - ACP-196 - afuresertib hydrochloride - AGS-67E - AT-7519 - AZD-6738 - BI-836826 - BMS-986016 - buparlisib hydrochloride - CBM-C19.1 - CBM-C20.1 - CC-122 - Cell Therapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - cerdulatinib - duvelisib - evofosfamide - FBTA-05 - GS-9901 - IMGN-529 - IMMU-114 - IPH-2201 - JCAR-014 - JCAR-015 - MEDI-551 - MOR-208 - moxetumomab pasudotox - nivolumab - obinutuzumab - pilaralisib - S-055746 - selinexor - spebrutinib besylate - TAK-659 - TGR-1202 - tisagenlecleucel-T For more information visit http://www.researchandmarkets.com/research/5m2c5s/refractory
IMMU: 2.05 (-0.06), PTLA: 49.44 (+0.53), IMGN: 18.02 (+0.12), TGTX: 17.45 (+0.39), BMY: 65.64 (+1.18), GSK: 43.44 (-0.15), GILD: 117.86 (-0.04), AZN: 33.79 (+0.05), JUNO: 48.92 (+1.15), INFI: 8.74 (+0.01), ABBV: 70.01 (-0.15), CBMG: 27.95 (+0.87), NVS: 103.75 (+0.57), KPTI: 20.52 (+0.44), CELGZ: 2.04 (+0.01)
1% Q2 Profit Growth Is S&P 500's Weakest Since '12
at Investor's Business Daily - Fri Jul 31, 7:02AM CDT
Six companies now are keeping the second-quarter earnings growth rate in positive territory for S&P 500 businesses, and that may suggest more softness to come. With 64% of S&P 500 companies having reported their performance in the last calendar...
DHI: 29.69 (+0.22), CCI: 81.91 (+0.44), F: 14.83 (-0.27), EMN: 78.40 (-0.19), FB: 94.01 (-1.20), UTX: 100.31 (-0.42), C: 58.46 (-0.42), WMT: 71.98 (-0.18), COP: 50.34 (-1.73), BAC: 17.88 (-0.25), AA: 9.87 (-0.11), LEN: 53.04 (+0.86), GILD: 117.86 (-0.04), CHK: 8.66 (-0.31), PHM: 20.72 (+0.32), GM: 31.51 (-0.40), GOOGL: 657.50 (-7.06), CAT: 78.63 (+0.28), CVX: 88.48 (-4.55), DOW: 47.06 (-0.36), AAPL: 121.30 (-1.07), VZ: 46.79 (+0.12)
Nokia and Whole Foods are big market movers
AP - Thu Jul 30, 3:24PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
WFM: 36.40 (+0.32), NHTC: 30.30 (-2.07), CNHI: 8.97 (unch), WYNN: 103.23 (-0.89), GSK: 43.44 (-0.15), CYT: 74.23 (-0.01), WDC: 86.06 (-0.38), NOK: 7.05 (+0.02), ATML: 8.28 (-0.14), GILD: 117.86 (-0.04), TMUS: 40.66 (+1.80), PG: 76.70 (-0.69), TWTR: 31.01 (-0.46), HOLX: 41.66 (+0.91)
Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)
Stock Market News for July 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 9:10AM CDT
Benchmarks ended higher on Wednesday after Fed’s policymakers kept key interest rates unchanged and acknowledged that the economy and job market are strengthening
RIG: 13.26 (-0.69), GILD: 117.86 (-0.04), NOC: 173.01 (-2.40), IP: 47.87 (+0.40), COP: 50.34 (-1.73), XOM: 79.21 (-3.80), CVX: 88.48 (-4.55), SLB: 82.82 (-0.70), MA: 97.40 (-1.01)
Gilead's Hepatitis C Dominance Unchecked By AbbVie
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 30, 7:04AM CDT
Source: Gilead Sciences via Google Maps. Worries that Gilead Sciences market dominance in treating hepatitis C would falter following the launch of AbbVie 's Viekira Pak this year have been mostly curbed after Gilead Sciences' stellar second...
GILD: 117.86 (-0.04), ABBV: 70.01 (-0.15)
Gilead Sciences Rises 2.33% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 29, 3:43PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $115.11 to a high of $119.46. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $117.15 on volume of 23.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 117.86 (-0.04)
Watch for Gilead Sciences to Potentially Pullback After Gaining 2.33% Yesterday
Comtex SmarTrend(R) - Wed Jul 29, 3:42PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $115.11 to a high of $119.46. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $117.15 on volume of 23.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 117.86 (-0.04)
Stocks Rally in Relief as Fed Stays Mum on September Hike
at The Street - Wed Jul 29, 3:11PM CDT
Stocks rally into the close after the Federal Reserve keeps rates unchanged.
TOT: 49.29 (+0.09), GILD: 117.86 (-0.04), COP: 50.34 (-1.73), YELP: 26.40 (+0.37), TWTR: 31.01 (-0.46), PTR: 98.39 (-1.72), SLB: 82.82 (-0.70), MA: 97.40 (-1.01), XLE: 69.38 (-1.55), HUM: 182.09 (-1.61)
Two Little Headlines and the End of Health Care
Dave Gonigam - Daily Reckoning - Wed Jul 29, 2:27PM CDT
This post Two Little Headlines and the End of Health Care appeared first on Daily Reckoning . Dave Gonigam explores the end of health care as we know it. Plus: What if we paid for groceries the way we pay for health care? And: Can you keep your...
GILD: 117.86 (-0.04)
Stocks Are Higher After Fed Leaves Rates Unchanged
at The Street - Wed Jul 29, 1:54PM CDT
Stocks extend session highs after the Federal Reserve leaves interest rates unchanged.
GILD: 117.86 (-0.04), COP: 50.34 (-1.73), YELP: 26.40 (+0.37), TWTR: 31.01 (-0.46), MA: 97.40 (-1.01), HUM: 182.09 (-1.61)
Q2 Earnings Season Halftime Report
ESTMZ - Wed Jul 29, 1:47PM CDT
And just like that, we’re already at the midpoint of the second quarter earnings season. Technically, we’re past that, with 264 S&P 500 companies reporting. As usual, we are in much better standing in regards to growth than we were at the...
VLO: 65.60 (+1.37), SPY: 210.50 (-0.32), GILD: 117.86 (-0.04), FB: 94.01 (-1.20), XOM: 79.21 (-3.80), CVX: 88.48 (-4.55), TWTR: 31.01 (-0.46), AAPL: 121.30 (-1.07), GOOG: 625.61 (-6.98), CELG: 131.25 (-0.63)
5 Big Stocks on Traders' Radars -- and What You Should Do With Them Now
at The Street - Wed Jul 29, 1:37PM CDT
Here's a technical look at how to trade some of the most active stocks on the market right now.
MU: 18.51 (-1.39), GILD: 117.86 (-0.04), CFG: 26.07 (-0.42), X: 19.47 (-0.62), BLDR: 15.04 (+0.29)
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Wed Jul 29, 11:30AM CDT
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 3.39 (+0.03), KNMD: (), VTAE: 10.11 (+0.08), LLY: 84.51 (-0.03), OMER: 16.10 (-0.06), JNJ: 100.21 (+0.37), ISIS: 54.93 (+1.76), OPK: 16.37 (-0.01), GILD: 117.86 (-0.04), AZN: 33.79 (+0.05), MRK: 58.96 (+0.44), CCXI: 8.24 (-0.30), VBLT: 6.00 (+0.02), NVS: 103.75 (+0.57)
Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - Wed Jul 29, 11:29AM CDT
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 117.86 (-0.04), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)
Stocks Turn Positive as Crude Inventories Drop
at The Street - Wed Jul 29, 9:50AM CDT
Stocks turn positive on Wednesday after a steeper-than-expected drop in crude supplies.
ANTM: 154.27 (-0.62), GILD: 117.86 (-0.04), YELP: 26.40 (+0.37), TWTR: 31.01 (-0.46), MA: 97.40 (-1.01), HUM: 182.09 (-1.61)
Cramer -- Gilead Has a ‘Fabulous’ Quarter, Tons of Merger Opportunities
at The Street - Wed Jul 29, 9:35AM CDT
Gilead Sciences not only beat earnings estimates but it can make a massive acquisition should it want to do so, Cramer says.
GILD: 117.86 (-0.04), XBI: 255.44 (+2.98), IBB: 382.53 (+3.73)
